MicroPort Receives SFDA Approval for GnRH Infusion Pump
On March 23th, 2012, MicroPort announced that the SFDA has approved its La Fenice®GnRH Infusion Pump, which is the first pulsatile GnRH infusion pump in China jointly developed by MicroPortLifesciences Co., Ltd.and Shanghai Ruijin Hospital.
GnRH Infusion Pump is designed to meet the needs of Chinese physicians and patients for the treatment of Idiopathic HypogonadotropicHypogonadism (IHH) which is also known as Kallmann Syndrome. Equipped with pulse infusion via micro pumptechnology, GnRH infusion pump stimulates hypophysis to excrete Follicle-Stimulating Hormone (FSH)/ luteinizing hormone (LH) by simulating pulse excretion of human gonadotropin-releasing hormone(GnRH) in order to make patients recover from abnormally physiological regulated function.
Kallmann syndrome is a genetic disorder marked by anosmia and hypogonadism. Abnormalities in various genes may cause a defect in the hypothalamus, causing a deficiency of gonadotropin-releasing hormone (GnRH); this in turn causes deficiency in FSH and LH levels. Kallmann syndrome is also called hypothalamic hypogonadism. GnRHpulse infusion have a significant effect on maintaining and increasing in secondary sex characters, a progressive improvement of deficiency of grown-up Growth Hormone (GH) and bone mineral density (BMD), makes a contribution to regain fertility, and reduces the risk of cardiovascular-related adverse events, which is the most ideal treatment for such disease in these days.